Related Experiment Video
Updated: May 2, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.1K
[Short- and medium-term tolerance of hypofractionated prostate radiotherapy with simultaneous integrated boost]
Laurène Larrivière1, Stephane Supiot2, Astrid Thomin1
1Service de radiothérapie, centre régional de cancérologie Henry-S.-Kaplan, centre hospitalier universitaire de Tours, 2, boulevard Tonnellé, Tours, France.
Summary
This study found that pelvic lymph node irradiation with a simultaneous hypofractionated prostate boost is safe for prostate cancer patients. The treatment showed low rates of severe urinary and digestive toxicity in the short and medium term.
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Context:
- Prostate cancer treatment often involves radiation therapy.
- Pelvic lymph node irradiation and simultaneous boost techniques are evolving.
- Assessing toxicity is crucial for treatment protocol evaluation.
Purpose:
- To evaluate the safety and toxicity of pelvic lymph node irradiation with a simultaneous hypofractionated prostate boost.
- To determine if this protocol leads to excess short and medium-term urinary and digestive toxicity.
- To assess the feasibility of this combined radiotherapy approach.
Summary:
- A retrospective study analyzed 63 patients with intermediate or high-risk prostate cancer treated with 65Gy to the prostate/seminal vesicles and 50Gy to pelvic lymph nodes.
- Toxicity was assessed using CTCAE v5.0, with a median follow-up of 15 months.
- Results showed low rates of severe (grade 3-4) acute toxicity (6% urinary, 0% digestive) and medium-term toxicity (7% urinary, 0% digestive).
Impact:
- The findings suggest that this radiotherapy protocol is feasible and well-tolerated.
- This approach offers a potentially effective treatment option with manageable side effects for prostate cancer.
- The study contributes to understanding the safety profile of advanced radiation techniques in prostate cancer management.
